Potentially. But we'd need a better idea of how much of a buffer they have given themselves. As you know, clinical trials always take longer than expected and cost significantly more than planned. But either way, they have demonstrated that they are financially savvy and don't waste money. If any biotech is going to be in time and under budget, it'll be IXC
